Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.
Crown Crafts reported second quarter fiscal 2027 results, with net income increasing to $1.3 million despite a decline in net sales to $19.0 million. The company achieved a significant gross margin expansion to 32.0%, driven by profitability initiatives and tariff refunds, and declared a quarterly dividend of $0.03 per share.
Term
Q2 2027
“We continue to execute well on our profitability initiatives with meaningful improvement this quarter in our gross profit, marketing and administrative expenses, and year-to-date operating cash flow.”
Olivia Elliott, President and Chief Executive Officer
“Our stronger profitability reflects our continued initiatives around efficiency and profitability, and our talented team is simultaneously focused on the development of additional higher-margin products and sales channels to grow both sales and profitability in the quarters ahead.”
Olivia Elliott, President and Chief Executive Officer
Farmer Mac's Board of Directors declared a quarterly dividend of $1.60 per share for all three classes of its common stock, payable on December 31, 2026. The Board also declared quarterly dividends for six series of its non-cumulative preferred stock (Series D, E, F, G, H, and I) payable in January 2027.
Dominos Pizza EVP, Chief Marketing Officer Katherine E. Trumbull Sells $122K of Stock
Katherine E. Trumbull, EVP, Chief Marketing Officer, sold 370 shares of Dominos Pizza Inc at $329.90 a share, worth $122K in total on Nov 10, 2026. Shares held after the trade: 5,785 (-6.0%).
Alpha Cognition Inc. appointed Caren Deardorf to its Board of Directors, effective November 11, 2026. Ms. Deardorf, a biotechnology executive with over 30 years of experience, will serve on the Audit and Governance and Nomination Committees. As part of her appointment, she received an initial grant of 755 restricted stock units and 1,020 stock options with an exercise price of $8.62 per share.
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
Franklin Covey Chief Product Officer Michael Sean Merrill Covey Sells $123K of Stock
Michael Sean Merrill Covey, Chief Product Officer, sold 8,000 shares of Franklin Covey Co at $15.43 a share, worth $123K in total on Nov 10, 2026. Shares held after the trade: 217,426 (-3.5%).
AEVEX Corp. filed its 10-Q for the period ending September 30, 2026, highlighting the recent acquisition of Maritime Applied Physics Corporation (BlackSea) and its ongoing integration. The company continues to operate as a non-accelerated filer and emerging growth company following its April 2026 initial public offering.
Loews V.P., C.A.O. and Treasurer Mark S. Schwartz Sells $414K of Stock
Mark S. Schwartz, V.P., C.A.O. and Treasurer, sold 3,725 shares of Loews Corp at $111.17 a share, worth $414K in total on Nov 11, 2026. Shares held after the trade: 8,355 (-30.8%).
GCT Semiconductor reported total net revenues of $3.96 million for the nine months ended September 30, 2026, an increase from $2.11 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $37.63 million for the period, driven by high operating expenses and a significant $9.23 million loss from the change in fair value of common stock warrant liabilities.
Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
York Space Systems Inc. appointed Brian D. Frantz as its permanent Chief Financial Officer, effective November 12, 2026. In connection with the appointment, the Board approved a compensation package including a $400,000 base salary, a 75% target bonus, and a prorated grant of 6,043 restricted stock units valued at approximately $1.5 million.
Colgate Palmolive EVP and Controller Gregory Malcolm Sells $402K of Stock
Gregory Malcolm, EVP and Controller, sold 4,100 shares of Colgate Palmolive Co at $97.97 a share, worth $402K in total on Nov 10, 2026. Shares held after the trade: 10,061 (-29.0%).
ICF International Chief Oper. & Fin. Officer James C. M. Morgan Sells $253K of Stock
James C. M. Morgan, Chief Oper. & Fin. Officer, sold 3,000 shares of ICF International, Inc. at $84.32 a share, worth $253K in total on Nov 10, 2026. Shares held after the trade: 46,683 (-6.0%).
Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.
U.S. Global Investors reported its first quarter fiscal 2027 results, achieving 18% revenue growth to $2.7 million and returning to operating profitability. The company saw a 14% year-over-year increase in average assets under management to $1.6 billion, driven largely by a 45% surge in gold and precious metals strategies.
Term
Q1 2027
“Gold miners continued to draw investor interest during the quarter, and that showed up in our asset levels. Average assets in our gold strategies are up more than 45% from a year ago. We believe disciplined, actively managed exposure to high-quality miners remains an important part of a diversified portfolio, and we’re pleased that more investors appear to agree.”
Frank Holmes, CEO and Chief Investment Officer
“Defense is no longer defined just by aircraft and ships. It’s increasingly being reshaped by artificial intelligence (AI), autonomous systems and cybersecurity. As governments around the world direct more spending toward national security, we believe WAR, our actively managed Smart Beta 2.0 ETF, gives investors targeted exposure to the companies driving that transformation.”
MediaAlpha repurchased 1,130,000 shares of its Class A common stock from an affiliate of White Mountains Insurance Group in a private transaction for approximately $16.0 million. The shares were purchased at $14.15 per share, representing a 5.5% discount to the previous day's closing price, and will be canceled and retired.
MultiSensor AI Holdings reported a net loss of $1.95 million for the quarter ended September 30, 2026, a slight increase from the $1.68 million loss in the prior year period. While nine-month revenue grew to $4.81 million from $4.16 million, the company continues to experience operating losses and negative cash flow from operations as it expands its SaaS capabilities and condition intelligence platform.
ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.
Term
Q3 2026
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Ryan J. Leib, CAO, sold 6,963 shares of Vertex, Inc. at $17.39 a share, worth $121K in total on Nov 9, 2026. Shares held after the trade: 810 (-89.6%).
Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.
Park Dental Partners reported third quarter 2026 revenue of $64.9 million, a 6% increase year-over-year driven by reimbursement trends and acquisitions. Net income rose 36.1% to $1.7 million, although diluted EPS decreased to $0.27 compared to $0.72 in the prior-year period. The company also highlighted the completion of the Village Family transaction, expanding its network into a fourth state.
Term
Q3 2026
“Third-quarter revenue increased 6%, supported by same-practice growth, an expanding affiliated doctor base and contributions from recently acquired practices. We have made meaningful progress adding clinical capacity and strengthening our platform, and our focus now is converting that capacity and revenue growth into improved productivity and stronger earnings performance.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
“The completion of the Village Family transaction represents an important step in our growth strategy and extends our affiliated practice network into a fourth state. We remain focused on disciplined integration, supporting our affiliated practices and executing against the opportunities already within our business.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
Loews Insider James S. Tisch Sells $27.6M of Stock
James S. Tisch sold 249,921 shares of Loews Corp at $110.07 to $111.25 a share (average $110.46) in 4 transactions, worth $27.6M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,809,389 (-0.9%).
Carlyle Private Equity Partners Fund, L.P. reported total assets of $477.3 million as of September 30, 2026, a significant increase from $59.0 million at the end of 2025. The fund's investment portfolio grew to a fair value of $280.4 million, supported by substantial cash and cash equivalents of $194.2 million.
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
Term
Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Wyndham Hotels & Resorts Chief Commercial Officer Scott R. Strickland Sells $957K of Stock
Scott R. Strickland, Chief Commercial Officer, sold 12,000 shares of Wyndham Hotels & Resorts, Inc. at $79.77 a share, worth $957K in total on Nov 9, 2026. Shares held after the trade: 29,490 (-28.9%).
Boeing EVP, Pres. & CEO, BGS David Christopher Raymond Sells $524K of Stock
David Christopher Raymond, EVP, Pres. & CEO, BGS, sold 2,994 shares of Boeing Co at $174.91 a share, worth $524K in total on Nov 9, 2026. Shares held after the trade: 38,456 (-7.2%).
Frontier Group Holdings EVP, Legal & Corporate Affairs Howard Diamond Sells $297K of Stock
Howard Diamond, EVP, Legal & Corporate Affairs, sold 35,401 shares of Frontier Group Holdings, Inc. at $8.40 a share, worth $297K in total on Nov 9, 2026. Shares held after the trade: 133,126 (-21.0%).
Frontier Group Holdings SVP, Human Resources Steve Schuller Sells $41.8K of Stock
Steve Schuller, SVP, Human Resources, sold 5,000 shares of Frontier Group Holdings, Inc. at $8.35 a share, worth $41.8K in total on Nov 10, 2026. Shares held after the trade: 89,324 (-5.3%).
American Homes 4 Rent (AMH) has published a formal investor presentation titled 'Investor Highlights–November 2026' to its website and filed it with the SEC. The presentation provides strategic updates on the company's single-family rental portfolio, development program, and 2026 financial guidance. The filing is a standard Regulation FD disclosure intended to provide current highlights to analysts and investors.